SCHEMBL9734348

SCHEMBL9734348

CCc1cccc(CC)c1C(C)C

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 6/20 0.50
GABRB2 P47870 5/20 0.50
LMNA P02545 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
DAO P14920 1/20 0.37
HTT P42858 1/20 0.36
MGLL Q99685 1/20 0.35
PDK2 Q15119 1/20 0.35
ADRA2A P08913 1/20 0.35
ADRA2B P18089 1/20 0.35
ADRA2C P18825 1/20 0.35
GABRG2 P18507 1/20 0.34
GABRB3 P28472 1/20 0.34
KCNH2 Q12809 1/20 0.34
SCN5A Q14524 1/20 0.34
ELANE P08246 3/20 0.34
ANPEP P15144 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20713445 0.89 GABRA1 (0.41) GABRA1GABRB2LMNASMN1; SMN2L3MBTL1
SCHEMBL3088973 0.86 GABRA1 (0.43) GABRA1GABRB2LMNASMN1; SMN2L3MBTL1
SCHEMBL12446949 0.84 GABRA1 (0.41) GABRA1GABRB2LMNASMN1; SMN2L3MBTL1
SCHEMBL21736785 0.84 GABRA1 (0.52) GABRA1GABRB2LMNASMN1; SMN2L3MBTL1
SCHEMBL9336892 0.84 GABRA1 (0.52) GABRA1GABRB2LMNASMN1; SMN2L3MBTL1
SCHEMBL15371487 0.84 GABRA1 (0.44) GABRA1GABRB2LMNASMN1; SMN2L3MBTL1
SCHEMBL6546378 0.84 L3MBTL1 (0.46) L3MBTL1DAO
SCHEMBL18243183 0.82 GABRA1 (0.54) GABRA1GABRB2LMNASMN1; SMN2L3MBTL1
SCHEMBL11883134 0.81 GABRA1 (0.43) GABRA1GABRB2LMNASMN1; SMN2L3MBTL1
SCHEMBL10701444 0.81 KDM4E (0.47) L3MBTL1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10683294-B2 5-5 fused rings as C5a inhibitors CHEMOCENTRYX, INC. (US) 2020-06-16 US disclosed
WO-2020073011-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH APJ RECEPTOR ACTIVITY ANNAPURNA BIO, INC. (US) 2020-04-09 WO disclosed
CN-1018908-B COLOR-DEVELOPING SHEETS USING IN PRESSURE-SENSING CARBON PAPER MITSUI TOATSU CHEMICALS (JP) 1992-11-04 CN disclosed
EP-0233450-B1 LINEAR SALICYLIC ACID COPOLYMERS AND THEIR METAL SALTS, PRODUCTION PROCESS THEREOF, COLOR-DEVELOPING AGENTS COMPRISING METAL-RESINS OF THE COPOLYMERS, AND COLOR-DEVELOPING SHEETS EMPLOYING THE AGENTS MITSUI TOATSU CHEMICALS, Inc. (JP) 1992-03-11 EP disclosed
CN-1007814-B Linear salicylic acid copolymer and method for producing metal salt thereof, and color-developing agent containing copolymer metal salt, and color-developing paper using the same MITSUI TOATSU CHEMICALS (JP) 1990-05-02 CN disclosed
CN-1040543-A Linear salicylic acid copolymer, process for producing metal salt thereof, color-developing agent containing copolymer metal salt, and color-developing paper using the same MITSUI TOATSU CHEMICALS (JP) 1990-03-21 CN disclosed
US-4783521-A Linear salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal-resins of the copolymers MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1988-11-08 US disclosed
CN-87100709-A Linear salicylic acid copolymer and method for producing metal salt thereof, and color-developing agent containing copolymer metal salt, and color-developing paper using the same 1987-09-02 CN disclosed
EP-0233450-A2 Linear salicylic acid copolymers and their metal salts, production process thereof, color-developing agents comprising metal-resins of the copolymers, and color-developing sheets employing the agents MITSUI TOATSU CHEMICALS, Inc. (JP) 1987-08-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683294-B2 5-5 fused rings as C5a inhibitors C5AR1, C5AR2, C3AR1 GABRA1 1492/4885GABRB2 2152/4885LMNA 3347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.